Press Release Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update Aug 12
Press Release Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update Aug 4
Press Release Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma Jul 29